Denali Therapeutics Inc
$ 24.83
0.40%
07 Aug - close price
- Market Cap 3,924,892,000 USD
- Current Price $ 24.83
- High / Low $ 25.74 / 24.25
- Stock P/E N/A
- Book Value 5.84
- EPS -2.88
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.50 %
- 52 Week High 27.30
- 52 Week Low 12.58
About
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$34.31
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-27 | 2024-11-06 | 2024-08-01 | 2024-05-07 | 2024-02-27 | 2023-11-07 |
| Reported EPS | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 | -0.63 | -0.59 | -0.78 | -0.86 | -0.72 |
| Estimated EPS | -0.72 | -0.71 | -0.75 | -0.76 | -0.74 | -0.7 | -0.8459 | -0.63 | -0.69 | -0.66 | -0.8 | -0.79 |
| Surprise | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | -0.08 | 0.1759 | 0 | 0.1 | -0.12 | -0.06 | 0.07 |
| Surprise Percentage | 5.5556% | 2.8169% | 2.6667% | 2.6316% | 2.7027% | -11.4286% | 20.7944% | 0% | 14.4928% | -18.1818% | -7.5% | 8.8608% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNLI
2026-08-08 07:10:17
Analysts have issued a "Moderate Buy" consensus rating for Denali Therapeutics Inc. (NASDAQ:DNLI), with an average 12-month price target of $35.92, significantly above its current trading price. This comes despite the company reporting a quarterly loss of $0.68 per share, which missed consensus estimates, although its revenue exceeded expectations. Institutional investors hold a substantial 92.92% stake in the company, with notable increases in holdings from firms like Goldman Sachs.
2026-08-08 06:10:17
Wall Street Zen has upgraded Denali Therapeutics (NASDAQ:DNLI) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $35.92. Despite missing quarterly EPS estimates, Denali reported higher-than-forecast revenue, and institutional investors hold a significant portion of its stock. The company is trading at $24.83, with a market capitalization of approximately $3.94 billion.
2026-08-07 18:10:17
Denali Therapeutics (DNLI) reported a narrower Q2 2026 loss of 68 cents per share, surpassing the Zacks Consensus Estimate. The company's net product revenues reached $3.6 million, driven by the strong initial commercial sales of its newly FDA-approved drug, Avlayah, for Hunter Syndrome. Denali's stock has seen a significant gain year-to-date, and it projects Avlayah net product revenues of $10.0 million to $12.0 million for Q3 2026.
2026-08-07 10:09:41
Wedbush has increased its price target on Denali Therapeutics Inc. (DNLI) to $27 from $26, while maintaining an Outperform rating. This adjustment comes shortly after Denali Therapeutics reported its Q2 2026 earnings, posting a loss of $0.68 per share but exceeding revenue expectations with $3.6 million. The company recently completed the sale of a Rare Pediatric Disease Priority Review Voucher for $195 million, contributing to recent financial activities.
2026-08-07 01:14:00
Denali Therapeutics reported strong financial results for Q2 2026, driven by the successful launch of AVLAYAH™, which generated $3.6 million in net product revenue. The company also announced the advancement of two Alzheimer’s disease programs into clinical development and received $195 million from the sale of a Priority Review Voucher, boosting its cash reserves to over $1.1 billion. Denali's TransportVehicle™ platform continues to be a key asset, enabling the delivery of biotherapeutics across the blood-brain barrier.
2026-08-07 00:09:42
Denali Therapeutics reported a Q2 2026 revenue miss, posting $3.6 million against an expected $11.94 million, and a wider-than-forecast loss of $0.68 per share. Despite the miss, the stock rose in after-hours trading as investors focused on the early, encouraging commercial launch of AVLAYAH, the company's first approved medicine, which generated $3.6 million in its first full commercial quarter. Denali provided Q3 revenue guidance for AVLAYAH between $10 million and $12 million, signaling accelerated growth driven by expanding payer coverage and physician adoption.
